A new study from Harvard Medical School has shown that NMN (Nicotinamide Mononucleotide) can improve weight loss, cholesterol levels, and blood pressure in overweight adults. You can read the original article here.
The study involved 100 overweight adults who participated in a 12-week program. Half of the participants received 100 mg of NMN daily, while the other half received a placebo. At the end of the study, the participants who received NMN had lost an average of 2.5 kilograms, while the placebo group had only lost 0.5 kilograms. The NMN group also had lower total cholesterol levels, lower LDL cholesterol levels (bad cholesterol), and higher HDL cholesterol levels (good cholesterol). Blood pressure was also lower in the NMN group compared to the placebo group.
The results of the study are promising and suggest that NMN could be an effective dietary supplement for improving the health of overweight adults. NMN is a natural molecule found in all living cells. It is an important precursor to NAD+ (Nicotinamide Adenine Dinucleotide), which is a crucial energy source for cells. NMN can also slow down cell aging and improve cell health.
This study is the first to investigate the effects of NMN on weight, cholesterol levels, and blood pressure in overweight adults.
NMN Could Be an Effective Dietary Supplement for Treating Obesity, High Cholesterol, and Hypertension: Harvard Medical School Study
The study yielded the following results:
- Side effects were similar in both groups. Treatment with MIB-626 significantly increased circulating NAD concentrations and its metabolites.
- Body weight (difference -1.9 [-3.3, -0.5] kg, P = 0.008); diastolic blood pressure (difference -7.01 [-13.44, -0.59] mmHg, P = 0.034); total cholesterol (difference -26.89 [-44.34, -9.44] mg/dL, P = 0.004), Low-Density Lipoprotein (LDL) cholesterol (-18.73 [-31.85, -5.60] mg/dL, P = 0.007), and non-High-Density Lipoprotein cholesterol decreased significantly more in the MIB-626 group than in the placebo group.
- Changes in muscle strength, muscle fatigue, aerobic capacity, and stair climbing power did not differ significantly between the groups. Insulin sensitivity and hepatic intra-abdominal fat did not change in either group.
This means that the side effects of MIB-626 were comparable to those of a placebo. However, MIB-626 significantly increased circulating NAD concentrations and significantly reduced body weight, diastolic blood pressure, total cholesterol, LDL cholesterol, and non-HDL cholesterol. There were no significant changes in muscle strength, muscle fatigue, aerobic capacity, stair climbing performance, insulin sensitivity, or hepatic intra-abdominal fat in either group.
It is important to note that the study included a small group of only 100 individuals. Further studies are needed to confirm the results.
What Is NMN?
NMN (Nicotinamide Mononucleotide) is a natural molecule found in all living cells. It is an important precursor to NAD+ (Nicotinamide Adenine Dinucleotide), which is a crucial energy source for cells. NMN can also slow down cell aging and improve cell health.
NMN is present in small amounts in food, such as fruits, vegetables, and grains.
NMN has been studied for its potential health benefits in several studies. These studies have shown that NMN can slow down cell aging, improve cell health, and extend lifespan. NMN also has the potential to treat a range of diseases such as cancer, Alzheimer’s, and heart disease.
It is important to note that most NMN studies are still in the early stages, and further research is needed to confirm the potential health benefits of NMN. In the EU, Nicotinamide Mononucleotide is not classified as a dietary supplement.
